Target Name: ACVR2B-AS1
NCBI ID: G100128640
Review Report on ACVR2B-AS1 Target / Biomarker Content of Review Report on ACVR2B-AS1 Target / Biomarker
Other Name(s): ACVR2B antisense RNA 1

Introduction to ACVR2B-AS1, A Potential Drug Target

ACVR2B-AS1 is a long non-coding RNA (lncRNA) that has recently gained attention in the field of biomedical research as a potential drug target or biomarker. In this article, we will explore the various aspects of ACVR2B-AS1, its role in diseases, and its potential implications in diagnostics and therapeutics.

Understanding ACVR2B-AS1

ACVR2B-AS1 is located on chromosome 2q32.1 and is transcribed in the opposite direction to the gene ACVR2B. LncRNAs are a class of RNA molecules that do not encode proteins but play essential roles in gene expression regulation and cellular processes. ACVR2B-AS1 has been shown to be involved in several physiological and pathological processes, including cancer, neurological disorders, and cardiovascular diseases.

ACVR2B-AS1 in Cancer

One area where ACVR2B-AS1 has garnered significant interest is its involvement in cancer progression and metastasis. Studies have shown that ACVR2B-AS1 is upregulated in various cancer types, such as lung, breast, colorectal, and pancreatic cancers. Its overexpression has been associated with increased tumor growth, invasion, and migration. Researchers have identified potential mechanisms by which ACVR2B-AS1 promotes cancer progression, including the regulation of gene expression, signaling pathways, and the modulation of cell cycle progression.

Potential Therapeutic Target

Due to its involvement in cancer progression, ACVR2B-AS1 has emerged as a potential therapeutic target. Inhibition of ACVR2B-AS1 has been shown to suppress tumor growth and metastasis in preclinical models. Different approaches are being explored to target ACVR2B-AS1, including antisense oligonucleotides, small interfering RNAs (siRNAs), and CRISPR-Cas9 gene editing. However, further research is needed to evaluate the safety and efficacy of these approaches before they can be translated into clinical practice.

ACVR2B-AS1 as a Biomarker

In addition to its potential as a drug target, ACVR2B-AS1 also holds promise as a biomarker for various diseases. Several studies have demonstrated the diagnostic and prognostic value of ACVR2B-AS1 in different cancer types. Elevated levels of ACVR2B-AS1 have been associated with advanced disease stages, poorer overall survival, and increased risk of metastasis. Therefore, the measurement of ACVR2B-AS1 expression levels in patient samples may serve as a non-invasive biomarker for cancer diagnosis, prognosis, and treatment response monitoring.

ACVR2B-AS1 in Neurological Disorders

Recent research suggests that ACVR2B-AS1 also plays a role in neurological disorders. Studies have shown its dysregulation in conditions such as Alzheimer's disease, Parkinson's disease, and stroke. It has been implicated in neuroinflammation, synaptic plasticity, and neuronal cell death. Exploring the therapeutic potential of targeting ACVR2B-AS1 in neurological disorders may open new avenues for intervention.


ACVR2B-AS1, a lncRNA located on chromosome 2q32.1, demonstrates diverse roles in diseases such as cancer and neurological disorders. Its dysregulation contributes to disease progression, making it an attractive candidate for targeted therapies or diagnostic biomarkers. However, further studies are necessary to unravel the underlying mechanistic pathways, evaluate its full therapeutic potential, and establish standardized diagnostic protocols. The continued exploration of ACVR2B-AS1 may bring us closer to developing novel treatments and diagnostic tools that could potentially improve patient outcomes in a range of diseases.

Protein Name: ACVR2B Antisense RNA 1

The "ACVR2B-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ACVR2B-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

ACVRL1 | ACY1 | ACY3 | Acyl-CoA dehydrogenase (ACAD) | Acyl-CoA Synthetase Short-Chain | ACYP1 | ACYP2 | ADA | ADA2 | ADA2A-containing complex (ATAC) | ADAD1 | ADAD2 | ADAL | ADAM10 | ADAM11 | ADAM12 | ADAM15 | ADAM17 | ADAM18 | ADAM19 | ADAM1A | ADAM1B | ADAM2 | ADAM20 | ADAM20P1 | ADAM21 | ADAM21P1 | ADAM22 | ADAM23 | ADAM28 | ADAM29 | ADAM30 | ADAM32 | ADAM33 | ADAM3A | ADAM5 | ADAM6 | ADAM7 | ADAM7-AS1 | ADAM7-AS2 | ADAM8 | ADAM9 | ADAMDEC1 | ADAMTS1 | ADAMTS10 | ADAMTS12 | ADAMTS13 | ADAMTS14 | ADAMTS15 | ADAMTS16 | ADAMTS16-DT | ADAMTS17 | ADAMTS18 | ADAMTS19 | ADAMTS2 | ADAMTS20 | ADAMTS3 | ADAMTS4 | ADAMTS5 | ADAMTS6 | ADAMTS7 | ADAMTS7P1 | ADAMTS7P3 | ADAMTS7P4 | ADAMTS8 | ADAMTS9 | ADAMTS9-AS1 | ADAMTS9-AS2 | ADAMTSL1 | ADAMTSL2 | ADAMTSL3 | ADAMTSL4 | ADAMTSL4-AS1 | ADAMTSL5 | ADAP1 | ADAP2 | Adapter protein complex 5 | Adaptor-related protein complex 1 | Adaptor-related protein complex 2 | Adaptor-Related Protein Complex 3 | Adaptor-related protein complex 4 | ADAR | ADARB1 | ADARB2 | ADARB2-AS1 | ADAT1 | ADAT2 | ADAT3 | ADCK1 | ADCK2 | ADCK5 | ADCY1 | ADCY10 | ADCY10P1 | ADCY2 | ADCY3 | ADCY4 | ADCY5 | ADCY6 | ADCY7